Calcium pyrophosphate dihydrate deposition disease

Changed by Brian Gilcrease-Garcia, 4 Nov 2018

Updates to Article Attributes

Body was changed:

Calcium pyrophosphate dihydrate disease (CPPD disease), also known as pyrophosphate arthropathy and perhaps confusingly asor pseudogout, is common, especiallydefined by the co-occurrence of arthritis with evidence of CPPD deposition within the articular cartilage.

It is mostly described in the elderly (>60 years old), and is characterised bydescribed as the depositionmost common cause of chondrocalcinosis.

Terminology 

The terminology regarding CPPD disease has been confusing, with chondrocalcinosis, CPPD, and pseudogout often used synonymously. Indeed, although initially described as chondrocalcinosis articularis, it is now understood that imaging findings of chondrocalcinosis do not always indicate CPPD disease 9.

In response, in 2011 the European League Against Rheumatism (EULAR) proposed a standardized terminology corresponding to clinical presentation 9:

  • CPPD - occurrence of calcium pyrophosphate in soft tissues and cartilage.

    Terminology 

    crystals, with or without symptoms
  • asymptomatic CPPD is one- chondrocalcinosis +/- changes of many causes of soft tissue calcification (chondrocalcinosis). It is not synonymous with chondrocalcinosis and not the only cause of soft tissue calcification.

    Where

    osteoarthritis, but clinically asymptomatic
  • acute CPPD crystal deposition causes acute clinical manifestation, the termarthritis (formerly pseudogout should be used.) - self-limiting synovitis in the setting of CPPD
  • osteoarthritis with CPPD Pyrophosphate arthropathy- typical changes of osteoarthritis is a term that describes arthropathy secondary to in the setting of CPPD
  • chronic CPPD depositioncrystal inflammatory arthritis

Clinical presentation

Most patients with imaging findings of CPPD are clinically asymptomatic.

Acute CPPD crystal arthritis (pseudogout) presents with severe acute or subacute pain, swelling, erythema, and warmth, of one or more joints and is usually self-limited. HoweverThe presentation classically resembles an acute gout attack. Unlike gout, it is often used indiscriminately to refer to chondrocalcinosis toomost commonly involves the knee and more commonly involves the upper joints (shoulder, elbow, wrist).

Chronic CPPD crystal inflammatory arthritis presents with chronic, intermittent painful swelling in the peripheral joints of upper and lower extremities. 

Epidemiology

CPPD is commonest in patients over the age of 50. Men and women are equally affected. 

Pathology

The crystals are weakly positively birefringent on polarised microscopy and have a rhomboid or rod shape. Causes

Causes of CPPD can be divided into:

Radiographic features

CPPD has many features of osteoarthritis with an unusual distribution, for example, they tend to be symmetric in distribution and involve non-weight bearing joints or, in the hands, mainly involve the intercarpal and MCP joints. 

Features of degenerative joint disease in joints that are not commonly affected by it (i.e. non-weight bearing joints):

Chondrocalcinosis can occur in many locations. Notable sites include:

Large subchondral cysts may be present.

It is controversial whether gout leads to calcification of articular fibrocartilage or hyaline cartilage 6. CPPD disease can be differentiated from gout on ultrasound given that echogenic monosodium urate crystals line the surface of articular cartilage, whereas echogenic CPPD calcifications are located within the cartilage itself 7.

Differential diagnosis

Possible imaging differential considerations include

See also

  • -<p><strong>Calcium pyrophosphate dihydrate disease (CPPD disease)</strong>, also known as <strong>pyrophosphate arthropathy </strong>and perhaps confusingly as <strong>pseudogout</strong>, is common, especially in the elderly, and is characterised by the deposition of calcium pyrophosphate in soft tissues and cartilage.</p><h4>Terminology </h4><p>CPPD is one of many causes of soft tissue calcification (<a href="/articles/chondrocalcinosis">chondrocalcinosis</a>). It is not synonymous with chondrocalcinosis and not the only cause of soft tissue calcification.</p><p>Where crystal deposition causes acute clinical manifestation, the term <a href="/articles/calcium-pyrophosphate-dihydrate-deposition-disease">pseudogout</a> should be used. <a href="/articles/pyrophosphate-arthropathy">Pyrophosphate arthropathy</a> is a term that describes arthropathy secondary to CPPD deposition. However, it is often used indiscriminately to refer to chondrocalcinosis too.</p><h4>Epidemiology</h4><p>CPPD is commonest in patients over the age of 50. Men and women are equally affected. </p><h4>Pathology</h4><p>The crystals are weakly positively birefringent on polarised microscopy and have a rhomboid or rod shape. Causes of CPPD can be divided into:</p><ul>
  • +<p><strong>Calcium pyrophosphate dihydrate disease (CPPD disease)</strong>, also known as <strong>pyrophosphate arthropathy </strong>or <strong>pseudogout</strong>, is defined by the co-occurrence of arthritis with evidence of CPPD deposition within the articular cartilage.</p><p>It is mostly described in the elderly (&gt;60 years old), and is described as the most common cause of <a href="/articles/chondrocalcinosis">chondrocalcinosis</a>.</p><h4>Terminology </h4><p>The terminology regarding CPPD disease has been confusing, with chondrocalcinosis, CPPD, and pseudogout often used synonymously. Indeed, although initially described as <em>chondrocalcinosis articularis</em>, it is now understood that imaging findings of chondrocalcinosis do not always indicate CPPD disease <sup>9</sup>.</p><p>In response, in 2011 the European League Against Rheumatism (EULAR) proposed a standardized terminology corresponding to clinical presentation <sup>9</sup>:</p><ul>
  • +<li>
  • +<strong>CPPD</strong> - occurrence of calcium pyrophosphate crystals, with or without symptoms</li>
  • +<li>
  • +<strong>asymptomatic CPPD </strong>- chondrocalcinosis +/- changes of osteoarthritis, but clinically asymptomatic</li>
  • +<li>
  • +<strong>acute CPPD crystal arthritis </strong>(formerly <a href="/articles/calcium-pyrophosphate-dihydrate-deposition-disease">pseudogout</a>) - self-limiting synovitis in the setting of CPPD</li>
  • +<li>
  • +<strong>osteoarthritis with CPPD</strong> <strong>- </strong>typical changes of <a href="/articles/osteoarthritis">osteoarthritis</a> in the setting of CPPD</li>
  • +<li><strong>chronic CPPD crystal inflammatory arthritis</strong></li>
  • +</ul><h4>Clinical presentation</h4><p>Most patients with imaging findings of CPPD are clinically asymptomatic.</p><p>Acute CPPD crystal arthritis (pseudogout) presents with severe acute or subacute pain, swelling, erythema, and warmth, of one or more joints and is usually self-limited. The presentation classically resembles an acute <a title="Gout" href="/articles/gout">gout</a> attack. Unlike gout, it most commonly involves the knee and more commonly involves the upper joints (shoulder, elbow, wrist).</p><p>Chronic CPPD crystal inflammatory arthritis presents with chronic, intermittent painful swelling in the peripheral joints of upper and lower extremities. </p><h4>Epidemiology</h4><p>CPPD is commonest in patients over the age of 50. Men and women are equally affected. </p><h4>Pathology</h4><p>The crystals are weakly positively birefringent on polarised microscopy and have a rhomboid or rod shape. </p><p>Causes of CPPD can be divided into:</p><ul>
  • -<li>wrist: <a title="Triangular fibrocartilage complex" href="/articles/triangular-fibrocartilage-complex">triangular fibrocartilage complex</a> and <a title="lunotriquetral ligament" href="/articles/lunotriquetral-ligament">lunotriquetral ligaments</a> </li>
  • +<li>wrist: <a href="/articles/triangular-fibrocartilage-complex">triangular fibrocartilage complex</a> and <a href="/articles/lunotriquetral-ligament">lunotriquetral ligaments</a> </li>

References changed:

  • 9. Zhang W, Doherty M, Bardin T et al. European League Against Rheumatism Recommendations for Calcium Pyrophosphate Deposition. Part I: Terminology and Diagnosis. Ann Rheum Dis. 2011;70(4):563-70. <a href="https://doi.org/10.1136/ard.2010.139105">doi:10.1136/ard.2010.139105</a> - <a href="https://www.ncbi.nlm.nih.gov/pubmed/21216817">Pubmed</a>

ADVERTISEMENT: Supporters see fewer/no ads

Updating… Please wait.

 Unable to process the form. Check for errors and try again.

 Thank you for updating your details.